Search Results - "Lathrop, Kate"

Sacituzumab Govitecan in patients with breast cancer brain metastases and recurrent glioblastoma: a phase 0 window-of-opportunity trial by Balinda, Henriette U., Kelly, William J., Kaklamani, Virginia G., Lathrop, Kate I., Canola, Marcela Mazo, Ghamasaee, Pegah, Sareddy, Gangadhara R., Michalek, Joel, Gilbert, Andrea R., Surapaneni, Prathibha, Tiziani, Stefano, Pandey, Renu, Chiou, Jennifer, Lodi, Alessia, Floyd, John R., Brenner, Andrew J.

“…Sacituzumab Govitecan (SG) is an antibody-drug conjugate that has demonstrated efficacy in patients with TROP-2 expressing epithelial cancers. In a xenograft…”
Get full text

ERα-related chromothripsis enhances concordant gene transcription on chromosome 17q11.1-q24.1 in luminal breast cancer by Lin, Chun-Lin, Tan, Xi, Chen, Meizhen, Kusi, Meena, Hung, Chia-Nung, Chou, Chih-Wei, Hsu, Ya-Ting, Wang, Chiou-Miin, Kirma, Nameer, Chen, Chun-Liang, Lin, Ching-Hung, Lathrop, Kate I, Elledge, Richard, Kaklamani, Virginia G, Mitsuya, Kohzoh, Huang, Tim H-M

“…Chromothripsis is an event of genomic instability leading to complex chromosomal alterations in cancer. Frequent long-range chromatin interactions between…”
Get full text

mTOR inhibition abrogates human mammary stem cells and early breast cancer progression markers by Bouamar, Hakim, Broome, Larry Esteban, Lathrop, Kate Ida, Jatoi, Ismail, Brenner, Andrew Jacob, Nazarullah, Alia, Gorena, Karla Moncada, Garcia, Michael, Chen, Yidong, Kaklamani, Virginia, Sun, Lu-Zhe

“…Mammary physiology is distinguished in containing adult stem/progenitor cells that are actively amending the breast tissue throughout the reproductive lifespan…”
Get full text

Use of Milestones and Development of Entrustable Professional Activities in 2 Hematology/Oncology Training Programs by Shumway, Nathan M, Dacus, Jennifer J, Lathrop, Kate I, Hernandez, Elizabeth P, Miller, Maria, Karnad, Anand B

“…The Next Accreditation System (NAS) increases the focus on educational outcomes and meaningful evaluation of learners. This requires that key clinical faculty…”
Get full text

Abstract PO1-20-09: A rare unilateral expression of hand-foot syndrome: a case report by Portillo, Daniela Urueta, Lathrop, Kate

“…Abstract Introduction: Hand-foot syndrome, also known as palmar-plantar erythrodysesthesia, is a common side effect observed in patients undergoing various…”
Get full text

Immunogenicity of SARS-CoV-2 messenger RNA vaccines in patients with cancer by Addeo, Alfredo, Shah, Pankil K., Bordry, Natacha, Hudson, Robert D., Albracht, Brenna, Di Marco, Mariagrazia, Kaklamani, Virginia, Dietrich, Pierre-Yves, Taylor, Barbara S., Simand, Pierre-Francois, Patel, Darpan, Wang, Jing, Labidi-Galy, Intidhar, Fertani, Sara, Leach, Robin J., Sandoval, Jose, Mesa, Ruben, Lathrop, Kate, Mach, Nicolas, Shah, Dimpy P.

“…Patients with cancer experience a higher burden of SARS-CoV-2 infection, disease severity, complications, and mortality, than the general population…”
Get full text

Poziotinib treatment in patients with HER2-positive advanced breast cancer who have received prior anti-HER2 regimens by Nasrazadani, Azadeh, Marti, Juan Luis Gomez, Lathrop, Kate, Restrepo, Alvaro, Leu, Szu-Yun, Bhat, Gajanan, Brufsky, Adam

“…Purpose Poziotinib is an irreversible pan-inhibitor of the human epidermal growth factor receptor (HER) that has shown acceptable tolerability and antitumor…”
Get full text

Phase II study of the combination of lenvatinib (L) and eribulin (E) in advanced solid tumors by Banwait, Ranjit Singh, Ko, Heidi Chwan, Michalek, Joel, Lathrop, Kate Ida, Bowhay-Carnes, Elizabeth Ann, Fotopoulos, Georgios, Elledge, Richard M., Karnad, Anand B., Kaklamani, Virginia G.

“…3158 Background: Tumor angiogenesis remains a focal point in cancer therapeutics, necessitating innovative strategies to counter resistance mechanisms…”
Get full text

Abstract PD1-07: A Phase 2 study of poziotinib in patients with HER2-positive metastatic breast cancer heavily pre-treated with HER2-targeted therapy by Brufsky, Adam, Zulfiqar, Malik, Peguero, Julio, Lathrop, Kate, Bhat, Gajanan, Lebel, Francois

“…Abstract Background: Poziotinib is a novel pan-HER inhibitor that irreversibly blocks the EGFR family of tyrosine-kinase receptors and inhibits the…”
Get full text

Abstract PS7-17: Exploring global clinical trial enrollment opportunities in high breast cancer mortality regions by Blaize, Jean-Pierre A, Acosta, Phillip P, Gonzalez, Isiah, Ott, Kristen E, Lathrop, Kate

“…Abstract BACKGROUND Globally, breast cancer is the most commonly diagnosed cancer and the most common cause of cancer death for women. Access to high quality…”
Get full text

CTNI-10. SACITUZUMAB GOVITECAN FOR BREAST CANCER BRAIN METASTASIS by Balinda, Henriette, Kelly, William, Ghamasaee, Pegah, Gilbert, Andrea, Michalek, Joel, Kaklamani, Virginia, Lathrop, Kate, Surapaneni, Prathibha, Floyd, John, Brenner, Andrew

“…Abstract Breast cancer brain metastasis (BCBM) is a challenge that significantly impacts patient prognosis and quality of life. Sacituzumab govitecan (SG), an…”
Get full text

Abstract P5-14-17: Declining the COVID-19 vaccination: An evaluation of why some high risk cancer patients decline vaccination by Lathrop, Kate I, Prieto, Eva, Viveros, Stefany, Riggs, Salyna, Balboa, Eva, Murray, Juanita, Evans, Cynthia, Arora, Sukeshi

“…Abstract The COVID-19 pandemic has created many challenges and barriers to care for patients on active cancer treatments including increased risk for morbidity…”
Get full text

Abstract P2-09-12: Optimizing genetic testing in Hispanic women with breast cancer by Garcia, Allysa Lynn, Akula, Niklesh, Derrick, Daniel Kade, Worrell, Christopher M, Lakhotia, Simren, Menon, Shwetha, Lathrop, Kate

“…Abstract Hispanic women with newly diagnosed breast cancer who qualify for genetic testing based on national guidelines are often not referred to genetic…”
Get full text

Abstract PD13-05: Delivery and activity of SN-38 by sacituzumab govitecan in breast cancer brain metastases by Brenner, Andrew J, Pandey, Renu, Chiou, Jennifer, Floyd, John, Surapreneni, Prathiba, Kaklamani, Virginia, Lathrop, Kate, Crownover, Richard, Tiziani, Stefano

“…Abstract BACKGROUND: Sacituzumab Govitecan (SG, TRODELVY™) is an FDA approved antibody drug conjugate for treatment of metastatic triple negative breast cancer…”
Get full text

Abstract PS5-31: Molecular markers of response to s-equol, a novel oral estrogen receptor (ER) beta agonist for triple negative breast cancer by Lathrop, Kate, Kaklamani, Virginia, Brenner, Andrew, Li, Rong, Nazarullah, Alia, Hackman, Sarah, Thomas, Courtney, Gelfond, Jonathan, Rodriguez, Marisa, Elledge, Richard

“…Abstract Introduction: Patients with TNBC breast cancer have inferior treatment outcomes compared to other breast cancer subtypes and targeted therapies are…”
Get full text

Assessing the demographics of fertility preservation discussions in cancer patients by Auster, Michael E, Janania Martinez, Michelle, Blaize, Jean-Pierre, Djoufack Djoumessi, Lakene Raissa, Warnecke, Brian, Pandya, Abhishek, Lathrop, Kate Ida

“…Abstract only 135 Background: Young adults undergoing cancer treatment often face increased risk of infertility. Despite current ASCO guidelines recommending…”
Get full text

Abstract P1-10-06: Effect of aging and mTOR inhibition on human mammary stem cells and early breast cancer progression markers by Broome, Larry E, Bouamar, Hakim, Lathrop, Kate, Jatoi, Ismail, Brenner, Andrew, Garcia, Michael, Nazarullah, Alia, Moncada, Karla, Kaklamani, Virginia, Sun, Lu-Zhe

“…Abstract Ductal carcinoma in situ (DCIS) is the most common form of breast cancer and is a predecessor to invasive carcinoma development. The origins for early…”
Get full text

Breast cancer treatment delays in a majority minority community: is there a difference? by Parsons, Helen M, Lathrop, Kate I, Schmidt, Susanne, Mazo-Canola, Marcela, Trevino-Jones, Jessica, Speck, Heather, Karnad, Anand B

“…Recent studies from large nationwide cancer databases have consistently shown that Hispanic women with breast cancer have delays in treatment initiation…”
Get full text

Genomic and transcriptomic landscape of HER2-low breast cancer by Bansal, Rani, Adeyelu, Tolulope, Elliott, Andrew, Walker, Phillip, Bustos, Matias A, Rodriguez, Estelamari, Accordino, Melissa K, Meisel, Jane, Gatti-Mays, Margaret E, Hsu, Emily, Lathrop, Kate, Kaklamani, Virginia, Oberley, Matthew, Sledge, George, Sammons, Sarah L, Graff, Stephanie L

“…Novel agents have expanded the traditional HER2 definitions to include HER2-Low (HER2L) Breast Cancer (BC). We sought to evaluate the distinct molecular…”
Get full text

Abstract PO2-06-03: Meta-Analysis of Clinical Characteristics and Outcomes in Breast Cancer Patients with Visceral Crisis by Auster, Michael, Benkhadra, Raed, Lee, Sophia, Aldawoodi, Tamarah, Prokop, Larry, Nayfeh, Tarek, Datta, Paromita, Lathrop, Kate

“…Abstract Background: Recent advancements in novel therapeutics have resulted in improved survival over the last decade for patients with metastatic breast…”
Get full text